Expanding Horizons $20.677M Market Capitalization Optimi Health Corp. (OPTI.C) announced today that it has entered into a supply agreement with SABI Mind. According to the terms of the agreement,…
psilocin
Filament Health (FH.E) inked a supply deal with Optimi Health (OPTI.C) for psilocybin mushrooms for testing and analysis by Filament’s research team. These mushrooms come at the behest of…
Our Psychedelic Trip Isn’t Over I don’t know the first thing about psychedelics. Rather, that’s what I would have been saying back in 2020 when the psychedelics sector…
Counting to Four $25.537M Market Capitalization Filament Health Corp. (FH.NE) announced today that it has been issued a fourth patent for the extraction and standardization of natural psilocybin and…
Natural Psychedelics Revolution $21.418M Market Capitalization Filament Health Corp. (FH.NE) announced today that it has entered into an exclusive licensing agreement with Psyence Group Inc. (PSYG.C). Under the terms…
Patent Issuance $18.123M Market Capitalization Filament Health Corp. (FH.NE) announced today that it has been issued a patent by the United States Patent and Trademark Office (USPTO) for the…
Meeting with the FDA $18.123M Market Capitalization Filament Health Corp. (FH.NE) announced today that it has held a pre-investigational new drug application (PIND) meeting with the FDA Division…
Two for Two $23.066M Market Capitalization Filament Health Corp. (FH.NE) announced today that it has been issued a second patent by the Canadian Intellectual Property Office (CIPO) for the…
Algernon Pharmaceuticals (AGN.C) filed a combined clinical trials of investigational medicinal products and ethics approval application with the United Kingdom Medicines and Healthcare Products Regulatory Agency for its planned…
Filament Health Corp. (FH.NEO) announced today that the Company has received FDA authorization to initiate the first clinical trial using naturally-sourced psychedelic substances. Additionally, this is the first approval…